Background {#Sec1}
==========

The increased frequency of insulin treatment in adult patients with latent autoimmune diabetes (LADA) is a result of an accelerated pancreatic beta-cell loss due to autoimmune damage \[[@CR1]\]. The measurement of the endogenous insulin secretion may provide relevant insight into the comparison of the natural history of LADA with the natural histories of types 1 and 2 diabetes; however, limited data are available regarding fasting or stimulated C-peptide secretion in LADA \[[@CR2]--[@CR8]\]. Stimulated C-peptide is currently accepted as the reference outcome for assessing beta-cell secretory response in trials studying the prevention of beta-cell loss in established autoimmune diabetes \[[@CR9]\]. In addition, no studies have assessed the insulin secretory response using the standardised mixed-meal tolerance test (MMTT) in patients with LADA. Therefore, the aim of our study was to assess the stimulated C-peptide response in LADA patients with different disease durations and to compare the results to those of subjects with type 2 and adult-onset type 1 diabetes.

Methods {#Sec2}
=======

Participants and clinical data {#Sec3}
------------------------------

In this cross-sectional study, we enrolled 32 subjects with LADA, 33 subjects with type 1 and 30 subjects with type 2 diabetes mellitus. A total of 11 study subjects, 4 with LADA and 7 with type 1 diabetes, were recruited in Hospital de Sant Pau. All other subjects were included at Hospital Arnau de Vilanova. All study subjects were 30 -- 70 years old at the time of diagnosis. Type 1 and type 2 diabetes mellitus were diagnosed according to the standard criteria as described previously \[[@CR8]\], and LADA was defined as patients aged 30 -- 70 years at the diagnosis of diabetes who did not require insulin for at least 6 months after diagnosis, with glutamic acid decarboxylase (GAD) autoantibody (GADAb) or tyrosine phosphatase autoantibody (IA-2Ab) positivity. The study was initially part of the Action LADA project that was extended locally for an additional period of 3 years \[[@CR10]\]. The study protocol was designed to recruit 10 subjects in the following disease duration categories for each group: 6 -- 18 months, 19 months -- 5 years, and 5 -- 10 years from diagnosis. This number of subjects was established based on previous studies that yielded clear differences when this sample size was used to compare LADA and type 2 diabetes \[[@CR1], [@CR2]\]. Thus, at least 30 patients of each diabetes type were included. None of the subjects had impaired kidney function, liver disease or any other condition known to interfere with the C-peptide response. Patients were included consecutively after they signed a written informed consent document. The study protocol was approved by the local Ethics Committee of the two centers where patients were recruited, i.e. Hospital de Sant Pau (Barcelona) and Hospital Arnau de Vilanova (Lleida).

For each subject, age, sex, weight, height, body mass index, and disease duration were obtained as recently described \[[@CR8]\]. The time to start of insulin was calculated as the time between the date of diagnosis and the date of the first insulin treatment. In addition, glucose and HbA1c levels were tested using standard laboratory assays. A detailed description of the methods was recently published \[[@CR8]\].

Antibody measurements {#Sec4}
---------------------

Antibodies to islet cell antigens (GADA65 and IA-2) were measured with two commercially available ELISA kits: GAD65 Autoantibody ELISA and IA-2 Autoantibody ELISA (both from DRG Diagnostic, Marburg, Germany), as previously described \[[@CR11], [@CR12]\]. Optimal cut-off values for positivity were set at 5 and 15 U/mL for GADAb and IA-2Ab, respectively. Both assays showed good performance when tested in the Diabetes Antibody Standardization Program Workshops. In the Diabetes Antibody Standardization Program Workshop 2007, sensitivities and specificities were 94% and 97% for GADAb, respectively, and 66% and 95% for IA-2Ab; in the Diabetes Antibody Standardization Program Workshop 2009, the figures were 82% and 95% for GADAb, and 60% and 100% for IA-2Ab, respectively.

Mixed meal tolerance test {#Sec5}
-------------------------

The test was performed following the same procedures as those described in the European C-Peptide Trial in which our group participated \[[@CR13]\]. Briefly, after an overnight fasting period, all study subjects were scheduled to start the test before 10 a.m. the next morning. Subjects were asked to withhold any short-acting insulin for at least 6 hours before the test. The standard meal consisted of 6 ml/kg of a Boost HP drink (Nestle Nutrition, Vevey, Switzerland); the subjects were given up to 360 ml for up to 5 minutes. C-peptide samples were collected at times -5 and 0 minutes before (the mean of these two values was taken as the fasting concentration), and 10, 20, 30, 60, 90 and 120 minutes after the final intake of the mixed-meal.

C-peptide was measured by a chemiluminescence assay (Immulite 2000, Siemens Medical Solutions Diagnostics, LA, USA), with reference values of 0.30 -- 2.4 nmol/l (intra and interassay coefficients of variation were less than 5%). The lower detection limit was 0.03 nmol/l. Any value below the lower detection limit was arbitrarily assigned a concentration of 0.029 nmol/l.

Statistical analysis {#Sec6}
--------------------

Continuous variables are expressed as the mean (± SD) or the median (interquartile range (\[IQR\]) where appropriate. Categorical variables are described using the absolute and relative frequencies. Variables with a skewed distribution were log-transformed before analysis. Comparisons between groups were performed using the non-parametric Mann--Whitney *U* test for numerical variables and the *χ*^2^ test for percentages. The area under the curve of C-peptide (AUCCP) was computed from all timed collections using the trapezoidal rule \[[@CR9]\]. The analyses of the AUCCP and peak C-peptide were adjusted for sex, body mass index, age, duration of diabetes, fasting glucose, HbA1c and basal C-peptide. The results were considered to be statistically significant if the two-sided p-value was less than 0.05. All analyses were performed with SPSS for Windows version 15.0 (Chicago, USA).

Results {#Sec7}
=======

The clinical characteristics of the study groups are shown in Table  [1](#Tab1){ref-type="table"}. There were no differences in terms of age, sex distribution and disease duration among the 3 study groups. As already found in previous studies in our setting \[[@CR8]\], type 2 diabetic subjects demonstrated better glycemic control than patients with LADA and type 1 diabetes. In addition, the frequency of insulin treatment was higher in LADA subjects than in type 2 diabetic subjects.Table 1**Clinical characteristics and C-peptide stimulated secretion of the 3 study groups**Type 1 diabetesType 2 diabetesLADAp ^a^p ^b^Women, n (%)17 (51.5%)9 (30%)11 (34.4%)0.1660.715Age, years46.9 (10.6)53.7 (12.9)49.6 (10.6)0.1700.260Disease duration, months^c^31 \[12--56\]31 (10 -- 83)38.5 \[13.5 -- 59\]0.6180.897BMI, kg/m^2^24.7 (4.2)30.1 (5.5)27.9 (4.8)0.0040.110Fasting glucose, mmol/l9.0 (3.49)7.44 (1.92)8.84 (3.45)0.9290.147HbA1c, %7.5 (1.4)6.9 (1.0)8.3 (2.4)0.2650.012HbA1c, mmol/mol58.4 (15.5)52.2 (11.4)67.6 (26.7)Insulin treatment, n (%)33 (100%)8 (26.7%)20 (62.5%)\<0.0010.005Sulphonylurea treatment, n (%)-8 (20%)5 (15.6%)-0.652Categories, n0.8670.7656 -- 18 m10101019 m -- 5 years1210105 -- 10 years111012AUC C-peptide, nmol/l^d^41.3 (46.4)275.5 (121.2)140.8 (102.2)\<0.001\<0.00119.2 (16.8 -- 54.9)245.1 (182.6 -- 370.8)112.1 (54.6 -- 231.2)Peak C-peptide, nmol/l^c,d^0.45 (0.50)3.01 (1.29)1.50 (1.05)\<0.001\<0.0010.16 (0.16 -- 0.60)2.54 (2.18 -- 3.67)1.44 (0.68 -- 2.32)^a^p value for comparisons between type 1 diabetes and LADA; ^b^p value for comparison between type 2 diabetes and LADA; ^c^distributed variables; ^d^peak and AUC C-peptide results are given as mean (SD) and also as median (IQR).

Concerning treatment of hyperglycemia, insulin treatment was more frequent in LADA than in type 2 diabetes (62.5% vs. 26.7; p = 0.005) (Table  [1](#Tab1){ref-type="table"}). The distribution of the number of insulin-treated type 2 diabetic subjects according to disease duration was 2, 3 and 3 in categories 6 --18 months, 19 months -- 5 years, and 5 -- 10 years, respectively. The corresponding distribution of insulin treatment in patients with LADA was 5, 6 and 9 in disease duration categories 6 --18 months, 19 months -- 5 years, and 5 -- 10 years, respectively. The frequency of sulphonylurea drug use was similar in patients with type 2 diabetes and LADA (not significantly different). Six type 2 diabetic subjects were under sulphonylureas, all with a disease duration longer than 5 years. Five patients with LADA were under sulphonylurea treatment (3 in the disease duration category 19 months -- 5 years, and 2 in the duration category 5 -- 10 years). Only one patient with LADA was treated with sitagliptin, without any other study subjects treated with a dipeptidylpeptidase -- 4 inhibitor.

Subjects with LADA showed a capacity of stimulated C-peptide secretion that is intermediate between types 1 and 2 diabetic patients, both in terms of the peak secretion and the AUCCP (Table  [1](#Tab1){ref-type="table"}). In LADA, these measures of insulin secretion were significantly lower than in type 2 diabetic subjects and significantly higher than in type 1 subjects. These differences remained unchanged after adjusting for other confounding variables as age, sex, body mass index, HbA1c and glucose. This lower residual insulin secretion capacity was also confirmed when subjects were stratified by disease duration (Figure  [1](#Fig1){ref-type="fig"}, and Additional files [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}). Detailed results for AUCCP and peak C-peptide secretion according to disease duration are shown in Additional files [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}. Most measures of C-peptide secretion were significantly different between patients with LADA and those with type 1 or type 2 diabetes; the only exception was the comparison between the sub-analysis of the peak C-peptide and AUCCP of LADA and type 2 diabetes in subjects with shorter diabetes duration (6 to 18 months).Figure 1**The results of the mixed-meal tolerance test (panel a: area under the curve; panel b: peak C-peptide) of the different study groups (33 with type 2, 32 with LADA and 30 with type 2 diabetes), stratified according to the duration of diabetes mellitus.** Footnote: Triangles, circles and squares denote mean values with 95% CI of C-peptide in type 1 diabetes, type 2 diabetes and LADA, respectively. The differences between LADA and type 1 and type 2 diabetes are statistically significant except for the comparison of the peak and AUCCP of LADA and type 2 diabetes in subjects with a shorter diabetes duration (6 to 18 months). The number of patients treated with insulin was 8 in the group of type 2 diabetes and 20 in the group of LADA. For further details, see Table  [1](#Tab1){ref-type="table"}, and Additional files [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}.

Concerning the stimulated C-peptide in insulin-treated patients, those with LADA showed a lower response that was lower than that of type 2 diabetic subjects. Patients with LADA showed an AUCCP (102.4 ± 112.3 nmol/l) and peak C-peptide (1.25 ± 1.08 nmol/l) that were below those of type 2 diabetes patients (AUCPP: 200.1 ± 91.7 nmol/l; peak C-peptide: 2.23 ± 0.85 nmol/l) (p = 0.043 and p = 0.038, respectively). This finding is specially relevant considering that the disease duration of this 2 sub-groups of insulin-treated patients is not different (type 2 diabetes: 45.6 ± 42.8 months; LADA: 46 ± 32.2 months). Concerning non-insulin treated patients, those with LADA also had a lower C-peptide response, with an AUCCP (174.7 ± 74.8 nmol/l) and peak C-peptide (1.92 ± 0.87 nmol/l) in comparison with type 2 diabetic patients (AUCPP: 302.9 ± 120.5 nmol/l; peak C-peptide: 3.29 ± 1.32 nmol/l) (p = 0.002 and p = 0.001, respectively).

Discussion {#Sec8}
==========

The current findings clearly show that subjects with LADA, as defined in the Action LADA, have a different capacity of meal-stimulated insulin secretion at different disease stages. This is the first study to use the standardised MMTT to assess the residual stimulated insulin secretion in LADA patients based on different periods of disease duration.

The current findings are consistent with some previous studies in the literature. The fasting C-peptide results are similar to the values found in previous studies \[[@CR3], [@CR4], [@CR6], [@CR8]\]. The current differences in fasting C-peptide confirm our previous findings in a larger population sample \[[@CR8]\]. Also, the results show a consistent lower stimulated C-peptide secretion in those patients with LADA with or without insulin-treatment with respect to the respective counterparts with type 2 diabetes. Hosszúfalusi et al. also described the same initial pattern of differences with type 1 and type 2 diabetes; however, C-peptide secretion in patients with longer-duration LADA overlapped with the values for type 2 diabetic patients. In addition, over 6 years of follow-up, two prospective cohort studies with subjects of Asian origin consistently showed a more rapid loss of insulin secretion in LADA, measured as fasting C-peptide, than in type 2 diabetes \[[@CR4], [@CR6]\].

However, the most relevant information concerning residual insulin secretion in patients with LADA comes from Swedish studies. A study by Carlsson et al. demonstrated a decreased glucagon- and arginine-stimulated C-peptide secretion in a small group of LADA patients when compared to antibody-negative type 2 diabetic subjects \[[@CR2]\]. Previously, the most relevant follow-up data of stimulated insulin secretion were described in sub-studies of a Swedish cohort of type 2 diabetic subjects \[[@CR1]\]. In this group glucose- and glucagon-stimulated insulin secretion were clearly different in autoimmune diabetes when compared to antibody negative type 2 diabetic patients up to 3 years after diagnosis. A comparison with type 1 diabetic subjects demonstrated improved insulin secretion in LADA that subsequently disappeared after 1 year of follow-up. In addition, data from a recent Swedish intervention study showed that during 36 months of follow-up, the glucagon stimulated C-peptide response decreased in patients with conventionally treated LADA \[[@CR7]\].

The main limitation of this study is its cross-sectional design. Ideally, the characterisation of the natural history of insulin secretion in LADA subjects would be analysed in prospective follow-up studies. Based on the results of the current study, a prospective characterisation of the time-course of the loss of the insulin secretory capacity and the comparison with other diabetes types would require a multi-centre study with long-term follow-up. Another limitation is the number of subjects studied; however, this is the first study to use the reference MMTT method to compare the stimulated C-peptide response in LADA to the responses in types 1 and 2 diabetes on different stages of disease duration.

Conclusions {#Sec9}
===========

The present study shows that the stimulated insulin secretion capacity in LADA is intermediate between that of types 1 and 2 diabetes. This finding provides new data and further contributes to the characterisation of the natural history of LADA.

In addition, the study results may be helpful for future intervention trials aimed at preserving the residual insulin secretory capacity in subjects with autoimmune diabetes. Potential future prevention trials should be designed accordingly.
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